Risperidone-induced QT prolongation following overdose correlates with serum drug concentration and resolves rapidly with no evidence of altered pharmacokinetics

Journal of Clinical Pharmacology

Volumn 51, Issue 7, 2011, Pages 1112-1115

  Pollak, P Timothy ^a,e   Verjee, Zulfikaral H ^b,c   Lyon, Andrew W ^d  

^a UNIVERSITY OF CALGARY   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^d CALGARY LABORATORY SERVICES   (Canada)

^e NONE   (Canada)

Author keywords

overdose; paliperidone; Risperidone (Risperdal); tachyarrhythmia

Indexed keywords

RISPERIDONE;

ADULT; ANTICHOLINERGIC SYNDROME; ARTICLE; BLOOD SAMPLING; CARDIOTOXICITY; CASE REPORT; CONVALESCENCE; DRUG BLOOD LEVEL; DRUG OVERDOSE; ELECTROCARDIOGRAPHY MONITORING; EMERGENCY CARE; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; PATIENT CARE; QT PROLONGATION; SUICIDE ATTEMPT; TACHYCARDIA; TANDEM MASS SPECTROMETRY; TELEMETRY;

ADULT; AFFECTIVE DISORDERS, PSYCHOTIC; ANTIPSYCHOTIC AGENTS; ARRHYTHMIAS, CARDIAC; FEMALE; HUMANS; OVERDOSE; RISPERIDONE; TREATMENT OUTCOME;

EID: 79958796619     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010376973     Document Type: Article

References (11)

1. Sue YJ, Shannon M. Pharmacokinetics of drugs in overdose. Clin Pharmacokinet. 1992 ; 23: 93-105
2. Megarbane B, Aslani AA, Deye N, Baud FJ. Pharmacokinetic/pharmacodynamic modeling of cardiac toxicity in human acute overdoses: utility and limitations. Expert Opin Drug Metab Toxicol. 2008 ; 4: 569-579 (Pubitemid 351890739)
3. Alvarez PA, Pahissa J. QT alterations in psychopharmacology: proven candidates and suspects. Curr Drug Saf. 2010 ; 5: 97-104
4. Ravin DS, Levenson JW. Fatal cardiac event following initiation of risperidone therapy. Ann Pharmacother. 1997 ; 31: 867-870 (Pubitemid 27332477)
5. Acri AA, Henretig FM. Effects of risperidone in overdose. Am J Emerg Med. 1998 ; 16: 498-501 (Pubitemid 28385615)
6. Lo Vecchio F, Hamilton RJ, Hoffman RJ. Risperidone overdose. Am J Emerg Med. 1996 ; 14: 95-96
7. Yasui-Furukori N, Mihara K, Kondo T, Kubota T, Iga T, Takarada Y, et al. Effects of CYP2D6 genotypes on plasma concentrations of risperidone and enantiomers of 9-hydroxyrisperidone in Japanese patients with schizophrenia. J Clin Pharmacol. 2003 ; 43: 122-127 (Pubitemid 36125937)
8. Darpo B, Nebout T, Sager PT. Clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs: the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 guideline. J Clin Pharmacol. 2006 ; 46: 498-507
9. Nishikage H, Nakanishi T, Takamitsu Y, Yamamoto J. Sequential changes in the plasma concentration of risperidone following intentional overdose. Clin Neuropharmacol. 2002 ; 25: 307-309 (Pubitemid 36025269)
10. Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AA, et al. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther. 1993 ; 54: 257-268 (Pubitemid 23294526)
11. Spina E, Avenoso A, Facciola G, Scordo MG, Ancione M, Madia A. Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine. Ther Drug Monit. 2001 ; 23: 223-227 (Pubitemid 32476548)